Clinical Phenotype of Respiratory Syncytial Virus Bronchiolitis before and during the Coronavirus Disease 2019 Pandemic

Abstract Objective  The main objective of this report was to comprehensively analyze the clinical characteristics of children hospitalized with respiratory syncytial virus (RSV) infections in 2021 during the coronavirus disease 2019 (COVID-19) pandemic and to compare them with those in the five previous RSV seasons. We hypothesized that the clinical and demographic features of children hospitalized with RSV infection in 2021 were different from those hospitalized in previous respiratory seasons. Study Design  In this retrospective observational study, children younger than 2 years hospitalized with RSV bronchiolitis from January 1, 2015, to December 31, 2021, at the Department of Pediatrics of the Hospital Gregorio Marañón, Madrid, Spain, were included. We compared the clinical characteristics of children hospitalized with RSV bronchiolitis in the five seasons before the COVID-19 pandemic and during the subsequent off-seasonal surge of RSV infections. Results  We found a significant reduction in hospitalizations for RSV bronchiolitis during the usual winter epidemic period due to the COVID-19 pandemic. Children hospitalized with RSV infection in 2021, during the COVID-19 pandemic, were older than children hospitalized in the prepandemic period (2015–2020; 4.0 [1.6–9.2] vs. 3 [1.5–6.5] months; p  < 0.01). We also found shorter duration of oxygen days during the COVID-19 period compared with previous respiratory seasons (3 [2–5] vs. 4 [2–6] days; p  = 0.02). Conclusion  The COVID-19 pandemic modified the RSV seasonality with a significant reduction in RSV hospitalizations during the expected 2020–2021 season and a reappearance of RSV 7 months later than expected. We also found changes in the median age of children with RSV bronchiolitis during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic compared with the prepandemic RSV seasons and shorter duration of oxygen days suggesting a modest reduction in disease severity. We hypothesize that this observation reflects the lack of RSV circulation in the previous months (April 2020-March 2021), with a larger pool of vulnerable infants that had not been previously infected. Key Points The COVID-19 pandemic shifted RSV seasonality. RSV children hospitalized during the pandemic were older. Modest reduction in disease severity was observed during the pandemic.

[1]  S. Madhi,et al.  Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis , 2022, The Lancet.

[2]  D. Buonsenso,et al.  Epidemiology, Microbiology and Severity of Bronchiolitis in the First Post-Lockdown Cold Season in Three Different Geographical Areas in Italy: A Prospective, Observational Study , 2022, Children.

[3]  D. Muscatello,et al.  RSV Epidemiology in Australia Before and During COVID-19. , 2022, Pediatrics.

[4]  Zhengrong Chen,et al.  Clinical Characteristics of Pediatric Respiratory Tract Infection and Respiratory Pathogen Isolation During the Coronavirus Disease 2019 Pandemic , 2022, Frontiers in Pediatrics.

[5]  L. Alcalá,et al.  SARS-CoV-2 B.1.1.7 Decline Is Not Driven by the Introduction of a More Successful Variant , 2021, Microbiology spectrum.

[6]  Q. Bassat,et al.  Acute bronchiolitis and respiratory syncytial virus seasonal transmission during the COVID-19 pandemic in Spain: A national perspective from the pediatric Spanish Society (AEP). , 2021, Journal of Clinical Virology.

[7]  C. Delacourt,et al.  Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France , 2021, European Journal of Clinical Microbiology & Infectious Diseases.

[8]  Wei Hao Lee,et al.  Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia , 2021, Archives of Disease in Childhood.

[9]  J. Avner,et al.  Delayed Seasonal RSV Surge Observed During the COVID-19 Pandemic , 2021, Pediatrics.

[10]  Wladimir J Alonso,et al.  Latitudinal Variations in Seasonal Activity of Influenza and Respiratory Syncytial Virus (RSV): A Global Comparative Review , 2013, PloS one.

[11]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[12]  L. Anderson,et al.  Clinical and epidemiologic features of respiratory syncytial virus. , 2013, Current topics in microbiology and immunology.

[13]  M. M. Mangues Bafalluy,et al.  [Subcutaneous adrenaline versus inhaled salbutamol in the treatment of childhood asthmatic crisis]. , 1987, Anales espanoles de pediatria.

[14]  W. P. Glezen,et al.  Risk of primary infection and reinfection with respiratory syncytial virus. , 1986, American journal of diseases of children.